88 related articles for article (PubMed ID: 1965375)
1. [Clinico-economical aspects of long-term therapy with moditen-depot].
Ushakov IuV; Kravchenko NE
Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(12):67-9. PubMed ID: 1965375
[TBL] [Abstract][Full Text] [Related]
2. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].
Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463
[TBL] [Abstract][Full Text] [Related]
3. [Effect of moditen-depot therapy on the duration and quality of remissions in schizophrenia patients].
Vovin RIa; Gurovich IIa; Eryshev OF; Zaĭtsev SG; Magalif AIu
Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(5):743-9. PubMed ID: 899478
[TBL] [Abstract][Full Text] [Related]
4. [Long-term moditen-depot treatment of schizophrenic patients at a psychoneurology dispensary].
Abramova LI; Gushanskiĭ EL
Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(3):419-24. PubMed ID: 3705854
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
[TBL] [Abstract][Full Text] [Related]
6. [Characteristics of the psychotropic activity of long-acting drugs (experience in the use of Moditen-depot)].
Smulevich AB; Minsker EI; Mazaeva NA; Volkova RP; Lukanina SK
Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(6):912-20. PubMed ID: 5050051
[No Abstract] [Full Text] [Related]
7. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
Tsutsul'kovskaia MIa; Minsker EI; Panteleeva GP; Mazurskii MB; Pekunova LG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(5):753-8. PubMed ID: 4718619
[No Abstract] [Full Text] [Related]
8. [Clinical observation on the effect of domestic fluphenazine decanoate in the treatment of schizophrenia---report of 431 cases (author's transl)].
Zhang YF
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Aug; 14(3):182-5. PubMed ID: 7333179
[No Abstract] [Full Text] [Related]
9. [Comparative study of the therapeutic effectiveness of mirenil prolongatum and moditen depot in the treatment of schizophrenia].
Afeltowicz Z; Sep-Kowalikowa B; Zgirski L
Psychiatr Pol; 1976; 10(5):479-85. PubMed ID: 981421
[No Abstract] [Full Text] [Related]
10. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
11. [Trial of a delayed-action neuroleptic, fluphenazine oenanthate (Moditen-retard, Squibb Lab.)].
Haumonté MT; Hoerdt HP
Ann Med Psychol (Paris); 1972 Feb; 1(2):277-83. PubMed ID: 5051257
[No Abstract] [Full Text] [Related]
12. [Results of long-term treatment with depot neuroleptics in schizophrenic patients].
Klein A; Ehle G
Psychiatr Neurol Med Psychol (Leipz); 1988 Mar; 40(3):159-67. PubMed ID: 3132729
[TBL] [Abstract][Full Text] [Related]
13. Stabilization and depot neuroleptic dosages.
Weiden P; Schooler NR; Severe JB; Lee JH; Schulz SC
Psychopharmacol Bull; 1993; 29(2):269-75. PubMed ID: 8290676
[TBL] [Abstract][Full Text] [Related]
14. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
Heresco-Levy U; Greenberg D; Lerer B; Javitt DC; Brown WA
Isr J Psychiatry Relat Sci; 1997; 34(4):281-9. PubMed ID: 9409085
[TBL] [Abstract][Full Text] [Related]
15. Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings].
Schooler NR; Levine J; Severe JB
Psychopharmacol Bull; 1979 Apr; 15(2):44-7. PubMed ID: 373006
[No Abstract] [Full Text] [Related]
16. [Experience with the depot neuroleptic LyogenR-depot].
Bach O; Petermann H; Geppert V
Psychiatr Neurol Med Psychol (Leipz); 1978 Sep; 30(9):563-6. PubMed ID: 733993
[TBL] [Abstract][Full Text] [Related]
17. The use of depot neuroleptics: clinical experience in the United States.
Kane JM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of therapeutically resistant paranoid schizophrenic patients with Moditen-depot combined with other psychotropic drugs and Leponex].
Gamburg AL; Aranovich AG; Kotel'kevich IuN; Omorokov BM; Rasniuk VA
Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(8):1211-6. PubMed ID: 6111169
[TBL] [Abstract][Full Text] [Related]
19. Dose response of prophylactic antipsychotics.
Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
[No Abstract] [Full Text] [Related]
[Next] [New Search]
